Financial Ratios Guard Therapeutics International AB
Equities
GUARD
SE0021181559
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.00 SEK | 0.00% | +4.32% | -18.99% |
08-29 | First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER | CI |
08-27 | Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -60.84 | -32.49 | -36.07 | -36.14 | -49.91 | |||||
Return on Total Capital | -110.99 | -38 | -39.77 | -40.22 | -58.85 | |||||
Return On Equity % | -181.77 | -60.89 | -64.22 | -63.91 | -92.85 | |||||
Return on Common Equity | -181.77 | -60.89 | -64.22 | -63.91 | -92.85 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | - | - | - | - | - | |||||
SG&A Margin | - | - | - | - | - | |||||
EBITDA Margin % | - | - | - | - | - | |||||
EBITA Margin % | - | - | - | - | - | |||||
EBIT Margin % | - | - | - | - | - | |||||
Income From Continuing Operations Margin % | - | - | - | - | - | |||||
Net Income Margin % | - | - | - | - | - | |||||
Net Avail. For Common Margin % | - | - | - | - | - | |||||
Normalized Net Income Margin | - | - | - | - | - | |||||
Levered Free Cash Flow Margin | - | - | - | - | - | |||||
Unlevered Free Cash Flow Margin | - | - | - | - | - | |||||
Asset Turnover | ||||||||||
Asset Turnover | - | - | - | - | - | |||||
Fixed Assets Turnover | - | - | - | - | - | |||||
Receivables Turnover (Average Receivables) | - | - | - | - | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 10.55 | 14.02 | 17.4 | 8.93 | 5.13 | |||||
Quick Ratio | 10.45 | 13.96 | 17.32 | 8.9 | 5.08 | |||||
Operating Cash Flow to Current Liabilities | -11.36 | -5.84 | -7.09 | -4.5 | -6.99 | |||||
Days Sales Outstanding (Average Receivables) | - | - | - | - | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 0.36 | - | - | - | - | |||||
Total Debt / Total Capital | 0.36 | - | - | - | - | |||||
LT Debt/Equity | 0.03 | - | - | - | - | |||||
Long-Term Debt / Total Capital | 0.03 | - | - | - | - | |||||
Total Liabilities / Total Assets | 17.41 | 12.65 | 7.7 | 12.46 | 21.7 | |||||
EBIT / Interest Expense | -50.78 | -5.75K | -81.28K | -114K | -22.98K | |||||
EBITDA / Interest Expense | -49.31 | -5.73K | -81.27K | -114K | -22.98K | |||||
(EBITDA - Capex) / Interest Expense | -49.4 | -5.73K | -81.27K | -114K | -22.98K | |||||
Total Debt / EBITDA | -0 | - | - | - | - | |||||
Net Debt / EBITDA | 1.25 | 2.24 | 2.32 | 1.77 | 0.73 | |||||
Total Debt / (EBITDA - Capex) | -0 | - | - | - | - | |||||
Net Debt / (EBITDA - Capex) | 1.25 | 2.24 | 2.32 | 1.77 | 0.73 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | - | - | - | - | - | |||||
Gross Profit, 1 Yr. Growth % | - | - | - | - | - | |||||
EBITDA, 1 Yr. Growth % | -40.34 | -7.33 | 101.87 | 39.8 | 1.14 | |||||
EBITA, 1 Yr. Growth % | -40.22 | -7.58 | 101.1 | 39.79 | 1.14 | |||||
EBIT, 1 Yr. Growth % | -48.54 | -9.05 | 101.1 | 39.79 | 1.14 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -47.92 | -10.79 | 103.63 | 37.56 | 0.43 | |||||
Net Income, 1 Yr. Growth % | -47.92 | -10.79 | 103.63 | 37.56 | 0.43 | |||||
Normalized Net Income, 1 Yr. Growth % | -47.92 | -10.79 | 103.63 | 37.56 | 0.43 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -90.95 | -45.39 | 51.36 | -12.91 | -29.66 | |||||
Accounts Receivable, 1 Yr. Growth % | - | - | - | - | - | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 22.57 | -91.47 | -34.09 | -48.28 | - | |||||
Total Assets, 1 Yr. Growth % | 133.59 | 43.17 | 108.76 | 6.39 | -57.93 | |||||
Tangible Book Value, 1 Yr. Growth % | -422.02 | 75.91 | 120.59 | 0.9 | -62.37 | |||||
Common Equity, 1 Yr. Growth % | -1.89K | 51.43 | 120.59 | 0.9 | -62.37 | |||||
Cash From Operations, 1 Yr. Growth % | 3 | -36.95 | 104.39 | 31.64 | 13.62 | |||||
Capital Expenditures, 1 Yr. Growth % | - | - | - | - | - | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 303.63 | -56.22 | 102.38 | 25.72 | 27.59 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 312.47 | -55.77 | 102.42 | 25.72 | 27.59 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | - | - | - | - | - | |||||
Gross Profit, 2 Yr. CAGR % | - | - | - | - | - | |||||
EBITDA, 2 Yr. CAGR % | -19.01 | -25.65 | 37.01 | 67.99 | 18.91 | |||||
EBITA, 2 Yr. CAGR % | -18.72 | -25.67 | 36.57 | 67.67 | 18.91 | |||||
EBIT, 2 Yr. CAGR % | -18.99 | -31.59 | 35.48 | 67.67 | 18.91 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -18.3 | -31.84 | 34.78 | 67.36 | 17.54 | |||||
Net Income, 2 Yr. CAGR % | -18.3 | -31.84 | 34.78 | 67.36 | 17.54 | |||||
Normalized Net Income, 2 Yr. CAGR % | -18.3 | -31.84 | 34.78 | 67.36 | 17.54 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -79.64 | -77.77 | -9.08 | 14.81 | -21.73 | |||||
Accounts Receivable, 2 Yr. CAGR % | - | - | - | - | - | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -17.38 | -67.67 | -76.29 | -41.61 | - | |||||
Total Assets, 2 Yr. CAGR % | 20.82 | 82.88 | 72.89 | 49.03 | -33.1 | |||||
Tangible Book Value, 2 Yr. CAGR % | 142.8 | 138.01 | 96.99 | 49.19 | -38.38 | |||||
Common Equity, 2 Yr. CAGR % | 28.31 | 420.7 | 82.76 | 49.19 | -38.38 | |||||
Cash From Operations, 2 Yr. CAGR % | -4.5 | -19.42 | 13.52 | 64.03 | 22.3 | |||||
Capital Expenditures, 2 Yr. CAGR % | - | - | - | - | - | |||||
Levered Free Cash Flow, 2 Yr. CAGR % < |